Friday 6 November 2026 Export AUPH’s income statement to Excel — free account

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024.

Revenue: +13.9%
EPS: 0.00%
Free cash flow: +4.41%
Total debt: −30.0%

Quarter to September 2026, against a year earlier

16.30 0.09 +0.56%

Follow AUPH

Alert me

Market cap: $2.2B
P/E: 6.8×
Fwd P/E: 17.6×
Dividend yield: —
F-score: 8/9
Altman Z: 7.86
Beneish M: −0.88
Dividend safety: n/a

Overview

Aurinia Pharmaceuticals Inc (AUPH) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Aurinia Pharmaceuticals Inc (AUPH) trades at a P/S ratio of 6.7×. Over the past ten years it has ranged from 3.6× (April 2024) to 16,785× (October 2020); the current reading is higher than 19% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/AUPH/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Aurinia Pharmaceuticals Inc P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/AUPH/metrics/ps-ratio">Aurinia Pharmaceuticals Inc (AUPH) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	7.6×	38.58%
FY2024	5.5×	(23.40%)
FY2023	7.1×	13.41%
FY2022	6.3×	(90.31%)
FY2021	64.9×	98.44%
FY2020	32.7×	(99.45%)
FY2019	5,927×	374.57%
FY2018	1,249×	39.93%
FY2017	892×	103.52%
FY2016	439×	29.22%

Period	P/S ratio	Change
Sep 2026	6.7×	(5.19%)
Jun 2026	7.1×	7.75%
Mar 2026	6.6×	(13.14%)
Dec 2025	7.6×	38.18%
43 more quarters	Free account

Against its own ten years

Low 3.6× High 16,785×

Ten-year median 290×

Current reading's percentile 20

Company	P/S ratio
VERA Vera Therapeutics, Inc. compare	n/m
BHVN Biohaven Ltd. compare	2.1×
ADMA ADMA Biologics Inc compare	5.7×
AUPH Aurinia Pharmaceuticals Inc	6.7×
LKFT Lakefront Biotherapeutics - Sponsored ADR compare	7.9×
VCEL Vericel Corporation compare	8.1×
PVLA Palvella Therapeutics, Inc. compare	54.1×
IMNM Immunome, Inc. compare	162×
CLDX Celldex Therapeutics, Inc. compare	2,498×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Aurinia Pharmaceuticals Inc (AUPH) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on AUPH

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on AUPH

Stockrow Weekly